• Dr. Martens published a transcript of its FY26 results presentation at its Brewer Street beacon store in London, attended by Chief Executive Officer Ije Nwokorie, Chief Financial Officer Giles Wilson, Chair Paul Mason, corporate communications and investor relations lead Bethany Barnes, and other executives.
• Revenue fell 1.4% on a constant-currency basis while adjusted PBT rose 59% to GBP 54.2 million on a constant-currency basis, supported by gross margin up 1.2% and adjusted EBIT margin rising to 10.4% from 7.7%.
• Management reclassified GBP 9.9 million of unlawful U.S. tariff costs from cost of goods and inventory into an operating expense adjusting item, with any future refunds to be treated as adjusting items; net bank debt fell GBP 25 million to just under GBP 70 million.
• Americas returned to growth on an underlying basis, with full-price DTC up 14% and U.S. off-price wholesale cut by about a third, lifting U.S. wholesale average selling price 23%; EMEA DTC remained weak, with full-price down 13% amid a highly promotional UK and Germany.
• Strategic priorities for FY27 included completing the full-price pivot in the UK and Germany, investing up to another 100 basis points in brand demand generation, upgrading 30 existing stores into “brand centres” over two years, and focusing on full-price boots while a new sandals program is slated to start late in the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Martens plc published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.